United Therapeutics Corporation (UTHR)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?
United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy
United Therapeutics is rated Buy, with a base case valuation of $535/share, despite recent revenue declines driven by competition from Liquidia's Yutrepia. Tyvaso DPI, UTHR's largest and still-growing product, is key; declines are isolated to older formulations, not the core dry powder franchise. Upcoming catalysts include FDA reviews for IPF and Ralinepag, with label expansion and new product launches potentially driving significant upside.
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions
United Therapeutics NASDAQ: UTHR outlined plans to expand its pulmonary fibrosis, pulmonary hypertension and organ-manufacturing businesses at the Bernstein Healthcare Leaders and Disruptors Conference, with management describing a pipeline of 14 prospective product launches and continued share repurchases.
United Therapeutics Corporation (UTHR) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
United Therapeutics Corporation (UTHR) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
United Therapeutics: Strong Catalyst Flow Bodes Well For Near-Term Growth
United Therapeutics has declined ~12% since my last review, reducing its market cap to ~$21.1 billion. My previous rating was "buy" based on a compelling 2026 Tyvaso franchise plus upcoming catalysts, reflecting valuation and risk considerations. UTHR's current "buy" investment thesis centers on upcoming PDUFA dates and other catalysts that could drive future growth and re-rate the stock.
Biotech Options Buzz: UTHR, NMRA, EWTX
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits.
United Therapeutics Corporation (UTHR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
United Therapeutics Corporation (UTHR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.
